| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NOV |
| Uniprot No | P48745 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 28-357aa |
| 氨基酸序列 | M+QVAATQRCP PQCPGRCPAT PPTCAPGVRA VLDGCSCCLV CARQRGESCS DLEPCDESSG LYCDRSADPS NQTGICTAVE GDNCVFDGVI YRSGEKFQPS CKFQCTCRDG QIGCVPRCQL DVLLPEPNCP APRKVEVPGE CCEKWICGPD EEDSLGGLTL AAYRPEATLG VEVSDSSVNC IEQTTEWTAC SKSCGMGFST RVTNRNRQCE MLKQTRLCMV RPCEQEPEQP TDKKGKKCLR TKKSLKAIHL QFKNCTSLHT YKPRFCGVCS DGRCCTPHNT KTIQAEFQCS PGQIVKKPVM VIGTCTCHTN CPKNNEAFLQ ELELKTTRGK M |
| 预测分子量 | 36.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NOV重组蛋白的模拟参考文献示例(实际文献需通过学术数据库核实)：
---
1. **"NOV (CCN3) as a Regulator of Cellular Signaling Pathways"**
*Brigstock, D.R. et al.*
摘要：探讨NOV蛋白(CCN家族成员)在调控Wnt和TGF-β信号通路中的作用，及其重组蛋白在体外抑制肿瘤细胞增殖的机制。
2. **"Functional Analysis of Recombinant CCN3/NOV in Chondrocyte Differentiation"**
*Kubota, S. & Takigawa, M.*
摘要：研究重组NOV蛋白对软骨细胞分化的影响，发现其通过整合素介导的MAPK通路促进软骨形成，为骨关节疾病治疗提供依据。
3. **"CCN Proteins in Fibrosis: Focus on NOV and CTGF"**
*Leask, A.*
摘要：分析NOV重组蛋白与CTGF的相互作用，揭示其在器官纤维化中的拮抗作用，提示NOV可能作为抗纤维化治疗的靶点。
4. **"Structural Characterization of Recombinant NOV Protein"**
*Perbal, B.*
摘要：报道NOV重组蛋白的纯化与结构解析，阐明其多结构域(TSP-1/IGFBP/VWC)对细胞粘附和凋亡的调控功能。
---
注：以上内容为学术示例，具体文献请通过PubMed/Google Scholar检索关键词(如“NOV/CCN3 recombinant protein”)获取。
NOV recombinant protein is derived from the NOV (Nephroblastoma Overexpressed) gene, a member of the CCN family of secreted matricellular proteins (CCN1–CCN6). The CCN family, named after its founding members CYR61. CTGF, and NOV, plays critical roles in regulating cell-matrix interactions, signaling pathways, and extracellular matrix (ECM) remodeling. NOV, also designated CCN3. is characterized by conserved modular structures, including insulin-like growth factor-binding (IGFBP), von Willebrand factor type C (VWC), thrombospondin type 1 (TSP1), and cysteine-rich C-terminal (CT) domains, which mediate its interactions with growth factors, integrins, and ECM components.
First identified in avian nephroblastoma, NOV is implicated in diverse physiological and pathological processes, such as cell proliferation, differentiation, angiogenesis, skeletal development, and tissue repair. Its expression is tightly regulated during embryogenesis but is often dysregulated in cancers, fibrosis, cardiovascular diseases, and metabolic disorders. NOV exhibits context-dependent roles—acting as either a tumor suppressor or promoter depending on tissue type, microenvironment, or post-translational modifications.
Recombinant NOV protein is produced using expression systems (e.g., bacterial, mammalian, or insect cells) to ensure proper folding and bioactivity. It serves as a vital tool for studying NOV’s molecular mechanisms, including its interactions with Notch, BMP, and Wnt pathways, or its role in modulating cell adhesion and migration. Therapeutic applications are being explored, particularly in regenerative medicine (e.g., bone/cartilage repair) and cancer therapy, where NOV’s dualistic functions necessitate targeted approaches. Challenges remain in elucidating its precise signaling networks and clinical potential, but ongoing research highlights NOV as a multifaceted regulator of cellular homeostasis and disease progression.
×
